Please select the option that best describes you:
Topics:
Radiation Oncology • Genitourinary Cancers
How do you incorporate absolute percent pattern 4 (APP4) into your risk stratification, specifically your recommendation for ADT for intermediate prostate cancer?
Given the importance of minimizing financial toxicity, for patients who have borderline unfavorable intermediate characteristics, is it reasonable to use APP4 in lieu of genomic/AI testing in low-resource patient settings to better select patients for ADT?
Answer from: Radiation Oncologist at Academic Institution
Summary: The short answer is that APP4 is unlikely to improve risk prognostication to the extent to which other advanced biomarkers (GC, MMAI, etc.) do. It is also unlikely either alone or in combination with standard clinical factors to serve as a predictive biomarker. Nevertheless, it is certainly...
Sign in or Register to read more